Beyond Weight Loss: Practical Considerations for use of Glucagon like Peptide-1 (GLP-1) and Incretin Therapy in Inflammatory Skin Disease
Résumé
The use of glucagon-like peptide-1 (GLP-1) based therapies has emerged as a topic in dermatology due to the strong bi directional association between obesity and immune-mediated inflammatory skin disease. The expanding benefits toward cardiometabolic health with GLP-1 and other incretin therapies supports the existence of a “skin-heart-metabolic” axis, prompting a shift from purely skin-directed therapies to holistic and systemic patient management. Dermatologists should be aware of the mechanisms, clinical evidence, safety profiles, and practical prescribing considerations of existing and novel drugs.
Références
Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. J Clin Invest. 2024;134(2):e175634. doi:10.1172/JCI175634
Wilding JPH, Batterham RL, Calanna S, Davies M, van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/nejmoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205 216. doi:10.1056/nejmoa2206038
Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. 2022;182:106320. doi:10.1016/j. phrs.2022.106320.
Lu C, Xie T, Guo X, Wu D, Li S, Li X, et al. Glucagon like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. Int Immunopharmacol. 2019;77:105969. doi:10.1016/j.intimp.2019.105969
Krajewski PK, Złotowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects J Clin Med. 2024;13(21):6292. doi:10.3390/jcm13216292
Paschou IA, Sali E, Paschou SA, Psaltopoulou T, Nicolaidou E, Stratigos AJ. The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review. Eur Acad Dermatol Venereol. 2025;39(12):2047-2055. doi:10.1111/ jdv.20694
Sheth S, Merola JF, Weber BN, Prussick R, Yeung J, Liu C, et al. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: a review. JAMA Dermatol. 2026;162(6):619-630. doi:10.1001/ jamadermatol.2026.0859
Katz A, Nong Y, Ma EJ, Roberts AM, Chou PP, Jeong CY, et al. Effects of GLP-1 receptor agonists on major cardiovascular events among patients with atopic dermatitis: a population-based study. Dermatitis. Published online February 6, 2026. doi:10.1177/17103568251410211
Lal K, Herringshaw E. The Use of GLP-1 agonists in the management of cutaneous disease. J Clin Aesthet Dermatol. 2024;17(9):34-37.
Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, et al. Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity: a phase 3b randomized clinical trial. JAMA Dermatol. Published online May 15, 2026. doi:10.1001/ jamadermatol.2026
Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial. Arthritis Rheumatol. Published online March 28, 2026. doi:10.1002/art.70134
Burshtein J, Armstrong A, Chow M, DeBusk L, Brad Glick, Gottlieb AB, et al. The association between obesity and efficacy of psoriasis therapies: an expert consensus panel. J Am Acad Dermatol. 2025;92(4):807–815. doi:10.1016/j.jaad.2024.12.016
Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: a scoping review. J Am Acad Dermatol. 2024;91(1):166-168. doi: 10.1016/j.jaad.2024.03.021
Paschou IA, Sali E, Paschou SA, Tsamis KI, Peppa M, Psaltopoulou T, et al. GLP-1RA and the possible skin aging. Endocrine. 2025;89(3):680-685. doi:10.1007/ s12020-025-04293-w
Fitch A, Gigliotti L, Bays HE. Application of nutrition interventions with GLP-1 based therapies: a narrative review of the challenges and solutions. Obes Pillars. 2025;16:100205. doi:10.1016/j.obpill.2025.100205
Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Saf. 2024;47(5):439-451. doi:10.1007/s40264-023-01392-3
